BlackRock’s Biotricity, Inc. Common Stock BTCY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q3
Sell
-13,375
Closed -$12K 5385
2024
Q2
$12K Hold
13,375
﹤0.01% 5051
2024
Q1
$19.8K Hold
13,375
﹤0.01% 5024
2023
Q4
$15.4K Hold
13,375
﹤0.01% 5114
2023
Q3
$28.6K Buy
13,375
+1
+0% +$2 ﹤0.01% 5091
2023
Q2
$51.2K Sell
13,374
-10,447
-44% -$39K ﹤0.01% 5063
2023
Q1
$66.5K Buy
23,821
+336
+1% +$1.38K ﹤0.01% 5059
2022
Q4
$63.1K Buy
23,485
+224
+1% +$1.24K ﹤0.01% 5165
2022
Q3
$112K Sell
23,261
-1,867
-7% -$13.1K ﹤0.01% 5150
2022
Q2
$267K Buy
25,128
+11,754
+88% +$103K ﹤0.01% 4960
2022
Q1
$182K Hold
13,374
﹤0.01% 5126
2021
Q4
$319K Buy
+13,374
New +$315K ﹤0.01% 4998

Other funds holding BTCY

BlackRock's BTCY Position: Q3 2024 in Review

BlackRock sold out of Biotricity, Inc. Common Stock (BTCY) in Q3 2024, closing a stake of 13,375 shares — an estimated $12K sold.

BlackRock first reported a position in BTCY in Q4 2021 and held it in 11 quarters. The position peaked at $319K in Q4 2021. 5 funds tracked by Wall St. Rank hold BTCY as of Q3 2024.

  • BlackRock reported no remaining Biotricity, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • BlackRock sold 13,375 Biotricity, Inc. Common Stock shares in Q3 2024, an estimated $12K.
  • BlackRock first reported a position in Biotricity, Inc. Common Stock in Q4 2021 and held it in 11 quarters.
  • BlackRock's Biotricity, Inc. Common Stock position peaked at $319K in Q4 2021.
  • 5 funds tracked by Wall St. Rank held Biotricity, Inc. Common Stock as of Q3 2024.

Based on BlackRock's 13F filing for Q3 2024, filed 13 Nov 2024.